The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol (EMBRACE)

Alexion Pharmaceuticals logo

Alexion Pharmaceuticals

Status

Conditions

Hemoglobinuria, Paroxysmal

Treatments

Drug: eculizumab

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT00438789
C06-002

Details and patient eligibility

About

The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • PNH;
  • At least 18 years old
  • Avoid conception; and
  • Willing and able to give written informed consent

Exclusion criteria

  • Active bacterial infection
  • Participation in any other drug trial
  • Pregnant breast feeding, or intending to conceive
  • Not vaccinated against N meningitidis

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems